Z
ZENAS BIOPHARMA, INC. COMMON STOCK
NASDAQ: ZBIO (Zenas BioPharma, Inc.)
Last update: 10 hours ago23.23
1.89 (8.86%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Zenas BioPharma, Inc. | - | - |
Stockmoo Score
0.8
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.75 |
|
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 23.61% |
| % Held by Institutions | 25.15% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 45.00 (Guggenheim, 93.72%) | Buy |
| Median | 37.50 (61.43%) | |
| Low | 27.00 (Citigroup, 16.23%) | Buy |
| Average | 36.75 (58.20%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 17.69 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 08 Oct 2024 | 27.00 (16.23%) | Buy | 17.69 |
| Guggenheim | 08 Oct 2024 | 45.00 (93.72%) | Buy | 17.69 |
| Jefferies | 08 Oct 2024 | 35.00 (50.67%) | Buy | 17.69 |
| Morgan Stanley | 08 Oct 2024 | 40.00 (72.19%) | Buy | 17.69 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |